- Home
- MOLN vs FENC Comparison
MOLN vs FENC Comparison
Compare MOLN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | FENC |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 276.3M |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MOLN | FENC |
|---|---|---|
| Price | $4.31 | $7.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.75 | ★ $13.50 |
| AVG Volume (30 Days) | 4.3K | ★ 188.6K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $999.99 | $70.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $4.68 |
| 52 Week High | $5.91 | $9.92 |
Technical Indicators
Market Signals| Indicator | MOLN | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 50.98 |
| Support Level | $4.16 | $7.51 |
| Resistance Level | $4.44 | $8.16 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 57.35 | 60.87 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.